Routes for drug delivery: Sustained-release devices

Developments in Ophthalmology

Volumn 55, Issue , 2015, Pages 84-92

  Yun, Samuel ^a   Huang, John J ^b  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Eye Disease Consultants   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DELAYED RELEASE FORMULATION; DRUG IMPLANT; LIPOSOME; NANOPARTICLE;

DELAYED RELEASE FORMULATION; DRUG ADMINISTRATION ROUTE; DRUG DELIVERY SYSTEM; DRUG IMPLANT; HUMAN; RETINAL DISEASES;

DELAYED-ACTION PREPARATIONS; DRUG ADMINISTRATION ROUTES; DRUG DELIVERY SYSTEMS; DRUG IMPLANTS; HUMANS; LIPOSOMES; NANOPARTICLES; RETINAL DISEASES;

EID: 84947220695     PISSN: 02503751     EISSN: 16622790     Source Type: Book Series    
DOI: 10.1159/000434692     Document Type: Article

References (30)

1. Del Amo EM, Urtti A: Current and future ophthalmic drug delivery systems: a shift to the posterior segment. Drug Discov Today 2008; 13:135-143.
2. Hsu J: Drug delivery methods for posterior segment disease. Curr Opin Ophthalmol 2007; 18:235-239.
3. Urtti A: Challenges and obstacles of ocular pharmacokinectics and drug delivery. Adv Drug Deliv Rev 2006; 58:1131-1135.
4. Davis JL, Gilger BC, Robinson MD: Novel approaches to ocular drug delivery. Curr Opin Mol Ther 2004; 6:195-205.
5. Bourges JL, Bloquel C, Thomas A, et al. Intraocular implants for extended drug delivery: therapeutic applications. Adv Drug Deliv Rev 2006; 58:1182-1202.
6. Musch DC, Martin DF, Gordon JF, et al. Treatment of cytomegalovirus retinitis with a sustained-release ganciclovir implant. N Engl J Med 1997; 335:83-90.
7. Dunn JP, Van Natta M, Foster G, et al. Complications of ganciclovir implant surgery in patients with cytomegalovirus retinitis: the Ganciclovir Cidofovir Cytomegalovirus Retinitis Trial. Retina 2004; 24:41-50.
8. Jaffe GJ, Martin D, Callanan D, et al. Fluocinolone acetonide implant (Retisert) for noninfectious posterior uveitis: thirty-four-week results of a multicenter randomized clinical study. Ophthalmology 2006; 113:1020-1027.
9. Goldstein DA, Godfrey DG, Hall A, et al. Intraocular pressure in patients with uveitis treated with fluocinolone acetonide implants. Arch Ophthalmol 2007; 125:1478-1485.
10. Jaffe GJ, Yang CH, Guo H, et al. Safety and pharmacokinetics of an intraocular fluocinolone acetonide sustained delivery device. Invest Ophthalmol Vis Sci 2000; 41:3569-3575.
11. Dugel PU, Eliott D, Cantrill HL, et al. I-vation™ TA: 24-month clinical results of the phase I safety and preliminary efficacy study. Proceedings of the Association for Research in Vision and Ophthalmology Annual Meeting, Fort Lauderdale, 2009.
12. ClinicalTrials.gov: A study of MK0140 in diabetic patients with macular edema (0140-001). http://clinicaltrials.gov/ct2/archive/NCT-00692614.
13. ClincalTrials.gov: Safety and preliminary efficacy study of PDS-1.0 in patients with neovascular AMD. http://clinicaltrials.gov/ct2/show/NCT01177644.
14. Kuppermann BD, Williams GA, Blumenkranz MS, et al. Efficacy and safety of a novel intravitreous dexamethasone drug-delivery system after applicator or incisional placement in patients with macular edema. Invest Ophthalmol Vis Sci 2006; 47:E-Abstract 5913.
15. Lee SY, Chee SP, Balakrishnan V, et al. Surodex in paediatric cataract surgery. Br J Ophthalmol 2003; 87:1424-1426.
16. ClinicalTrials.gov: Safety and efficacy of brimonidine intravitreal implant in patients with geographic atrophy due to age-related macular degeneration (AMD). http://clinicaltrials.gov/ct2/show/NCT00658619.
17. ClinicalTrials.gov: An exploratory study to evaluate the safety of brimonidine intravitreal implant in patients with retinitis pigmentosa. http://clinicaltrials.gov/ct2/show/NCT00661479.
18. ClinicalTrials.gov: Safety and efficacy of brimonidine tartrate posterior segment drug delivery system in improving visual function. http://clinicaltrials.gov/ct2/show/NCT00972374.
19. ClinicalTrials.gov: Safety and effects of brimonidine intravitreal implant in patients with glaucomatous optic neuropathy. http://clinicaltrials.gov/ct2/show/NCT00693485.
20. Ebrahim S, Peyman GA, Lee PJ: Applications of liposomes in ophthalmology. Surv Ophthalmol 2005; 50:167-182.
21. Bochot A, Fattal E, Boutet V, et al. Intravitreal delivery of oligonucleotides by sterically stabilized liposomes. Invert Ophthalmol Vis Sci 2002; 43:253-259.
22. Fattal E, Bochot A: Ocular delivery of nucleic acids: antisense oligonucleotides, aptamers, siRNA. Adv Drug Deliv Rev 2006; 58:1203-1223.
23. Moritera T, Ogura Y, Yoshmura N, et al. Biodegradable microspheres containing Adriamycin in the treatment of proliferative vitreoretinopathy. Invest Ophthalmol Vis Sci 1992; 33:3125-3130.
24. Bourges JL, Gautier SE, Delie F, et al. Ocular drug delivery targeting the retina and retinal pigment epithelium using polylactide nanoparticles. Invest Ophthalmol Vis Sci 2003; 44:3562-3569.
25. Fung AE: One-year safety and efficacy of an injectable, sustained-delivery, liquid steroid for treatment of macular edema due to retinal vein occlusion. Angiogenesis 2010, Miami, 2010.
26. ClinicalTrials.gov: 20089 TA+Lucentis Combo intravitreal injections for treatment of neovascular age-related macular degeneration (AMD) (20089/Combo). http://clinicaltrials.gov/ct2/show/NCT01175395.
27. Lim JI, Niec M, Hung D, et al. A pilot study of combination therapy for neovascular AMD using a single injection of liquid sustained release intravitreal triamcinolone acetonide and intravitreal ranibizumab as needed. Proceedings of the Association for Research in Vision and Ophthalmology Annual Meeting, Fort Lauderdale, 2012.
28. Sieving PA, Caruso RC, Tao W, et al. Ciliary neurotrophic factor for human retinal degeneration: phase I trial of CNTF delivered by encapsulated cell intraocular implants. Proc Natl Acad Sci U S A 2006; 103:3896-3901.
29. Guerrero-Naranjo JL, Quiroz-Mercado H, Sanchez-Bermudez G, et al. Safety of implantation of the NT-503 device in patients with choroidal neovascularization secondary to age-related macular degeneration. Proceedings of the Association for Research in Vision and Ophthalmology Annual Meeting, Seattle, 2013.
30. Yasukara T, Ogura Y, Tabata Y, et al. Drug delivery system for vitreoretinal diseases. Prog Retin Eye Res 2004; 23:253-281.